ABSTRACT
Systemic Gordonia spp. infections are rare and occur mostly among immunocompromised patients. We analyzed 10 cases of Gordonia bacteremia diagnosed in 3 tertiary care centers in France to assess risk factors, treatment, and clinical outcomes. Most patients were cured within 10 days by using ß-lactam antimicrobial therapy and removing central catheters.
Subject(s)
Bacteremia , Gordonia Bacterium , Humans , Risk Factors , Bacteremia/diagnosis , Bacteremia/drug therapy , Bacteremia/epidemiology , France/epidemiology , Immunocompromised HostSubject(s)
Autoimmune Diseases/drug therapy , COVID-19/pathology , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , Rituximab/adverse effects , Rituximab/therapeutic use , Aged , Antigens, CD20/drug effects , Humans , Male , Middle Aged , SARS-CoV-2/immunology , Viral Load/drug effectsABSTRACT
INTRODUCTION: Aerococccus urinae (AU) is a pathogen mainly identified in male urinary tract infections and responsible for bacteremia and endocarditis. To the best of our knowledge, there are only five patients with osteomyelitis due to AU described in the literature. All of them had urinary tract disease or systemic conditions such as diabetes, and two were associated with an endocarditis. CASE REPORT: We described the first case of isolated spondylodiscitis without general or local predisposing condition, excepted age > 65 years.
